

## Bangladesh

### Support for Vaccine: Measles Rubella This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Bangladesh						
2. Vaccine grant number:	18-BGD-18e-A, 19-BGD-18e-A, 20-BGD-18e-A						
3. Date of Decision Letter:	30/09/2019						
4. Date of the Partnership Framework Agreement:	24 June 2013						
5. Programme title:	New Vaccine Support (NVS), Measles Rubella, 2D Routine (Fragility, emergencies and refugees policy)						
6. Vaccine type:	Measles Rubella						
7. Requested product presentation and formulation of vaccine:	Measles Rubella, 10 dose(s) per vial, LYOPHILISED						
8. Programme Duration: <sup>1</sup>	2018-2020						
9. Programme Budget (indicative): <sup>2</sup>	(subject to the terms of the Partnership Framework Agreement)						
	2018-2019	2020	2021	2022	2023	2024	Total <sup>2</sup>
Programme Budget (US\$)	494,500	134,000	-	-	-	-	628,500
10. Vaccine introduction grant	Not applicable						
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts: <sup>3</sup>	(subject to the terms of the Partnership Framework Agreement)						
Type of supplies to be purchased with Gavi funds	2018-2019	2020	2021				
Number of vaccine doses		197,700	-				
Annual Amounts (US\$)	494,500	134,000	-				
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.						

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

**14. Self-procurement:** Not applicable

**15. Co-financing obligations:**

According to the co-financing policy, the Country falls within the group: Preparatory transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	21,900	-	-	-	-
Number of AD syringes	14,500	-	-	-	-
Number of re-constitution syringes	2,500	-	-	-	-
Number of safety boxes	200	-	-	-	-
Value of vaccine doses (US\$)	14,359	-	-	-	-
Total co-financing payments (US\$) (including freight)	16,000	-	-	-	-

**16. Operational support for campaigns:**  
Not applicable

**17. Additional Reporting Requirements:**

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2020 15 May 2020 N/A
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

**18. Financial clarifications:** Country shall provide the following clarifications to Gavi\*:

Not applicable

\* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.

**19. Other conditions:**

Not applicable

*Signed by,*

**On behalf of Gavi**



Thabani Maphosa

Managing Director, Country Programmes a.i.

30 September 2019